Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 7/20 | 0.56 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ERN1 | O75460 | 4/20 | 0.52 |
| ▸ | PLAT | P00750 | 2/20 | 0.50 |
| ▸ | PLG | P00747 | 1/20 | 0.50 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.50 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.50 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.49 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29452998 | 0.92 | ANO1 (0.58) | ANO1RAB9A | |
| SCHEMBL4725130 | 0.92 | ANO1 (0.58) | ANO1RAB9A | |
| SCHEMBL13701695 | 0.85 | HDAC8 (0.64) | ANO1 | |
| SCHEMBL13701694 | 0.85 | KAT6A (0.56) | PLAUANO1PLATPLGRAB9A | |
| SCHEMBL67941 | 0.85 | CA12 (0.68) | PLAUCA12CA9CA1CA2 | |
| SCHEMBL13701654 | 0.84 | RXRA (0.59) | RAB9A | |
| SCHEMBL13701631 | 0.84 | HDAC8 (0.54) | CDK8PDK2RAB9A | |
| SCHEMBL27715902 | 0.83 | CA12 (0.71) | PLAUCA12CA9CA1CA2 | |
| SCHEMBL13701672 | 0.83 | PLAU (0.48) | PLAUERN1PLATCDK8 | |
| SCHEMBL13701677 | 0.83 | KDM4E (0.50) | ANO1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | FLECK ROMAN WOLFGANG | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227588-A1 | Substituted pyrazole compounds useful as soluble epoxide hyrolase inhibitors | EPHX1, EPHX2, EPX | PLAU 592/4885ANO1 4532/4885CA12 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.